Nurix Therapeutics
NRIX
103 hedge funds and large institutions have $1.05B invested in Nurix Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 16 reducing their positions, and 14 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 16
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
2% more funds holding
Funds holding: 101 → 103 (+2)
4.18% less ownership
Funds ownership: 93.29% → 89.11% (-4.2%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
18% less capital invested
Capital invested by funds: $1.28B → $1.05B (-$237M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$28.1M |
| 2 |
ROTUOC
Regents of the University of California
Oakland,
California
|
+$16.8M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$14.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$14.1M |
| 5 |
Morgan Stanley
New York
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Column Group
San Francisco,
California
|
-$167M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$31.9M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$3.64M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$2.93M |
| 5 |
PCM
Pinz Capital Management
New York
|
-$2.25M |
NRIX Hedge Fund Activity: Q2 2021 in Review
103 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q2 2021, worth a combined $1.05B — down 18% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NRIX positions and 14 closed out — a net gain of 3 holders — while 52 added to existing stakes and 16 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $28.1M. The largest seller was Column Group, exiting entirely with an estimated $167M sold.
- 103 institutional investors held Nurix Therapeutics (NRIX) as of Q2 2021, up from 101 in Q1 2021.
- Funds reported $1.05B of Nurix Therapeutics stock for Q2 2021, down 18% quarter-over-quarter.
- 17 funds opened new Nurix Therapeutics positions in Q2 2021 and 14 closed out, a net change of +3 holders.
- The largest Nurix Therapeutics buyer in Q2 2021 was T. Rowe Price Associates, an estimated $28.1M added.
- The largest Nurix Therapeutics seller in Q2 2021 was Column Group, an estimated $167M sold.
Based on aggregated 13F filings for Q2 2021.